Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | ALPL | P05186 | 4/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746755 | 0.82 | MAPT (0.49) | HSD11B1ALPLCRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL5872525 | 0.80 | HSP90AA1 (0.45) | HSD11B1ALPLHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL12554990 | 0.78 | KMT2A (0.49) | HSD11B1ALPLPOLBKMT2A | |
| SCHEMBL24962591 | 0.76 | IKBKB (0.41) | KMT2A | |
| SCHEMBL27082554 | 0.74 | JAK2 (0.56) | ALPLDPP4DPP8 | |
| SCHEMBL5488856 | 0.74 | CRHR1 (0.45) | HSD11B1ALPLCRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL955251 | 0.74 | MAPT (0.52) | ALPLPOLBKMT2AKDM4EDPP4 | |
| SCHEMBL953237 | 0.73 | ALPL (0.52) | ALPLKDM4E | |
| SCHEMBL29624840 | 0.73 | AHR (0.64) | HSD11B1CRHR1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL464507 | 0.73 | AHR (0.64) | HSD11B1CRHR1HSP90AA1HSP90AB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1587473-A4 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1587473-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | HSD11B1 2564/4885ALPL 2901/4885CRHR1 4294/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | HSD11B1 2621/4885ALPL 3100/4885CRHR1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.